InvestorsHub Logo
Followers 4
Posts 326
Boards Moderated 0
Alias Born 10/19/2005

Re: None

Wednesday, 12/19/2012 10:38:37 AM

Wednesday, December 19, 2012 10:38:37 AM

Post# of 130505
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories because there is no conspiracy going on.

I would pay a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.

http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s

AMBS is only worth $11-12 Million right now.

Versus $250 Million.

Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.

In their own words:

"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."